SRSimon Ruffell

Simon Ruffell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Simon Ruffell has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • WaiFung Tsang

    Kings College London, Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom

    5 shared publications
  • Daniel Perkins

    Psychae Institute, Melbourne, Australia; Centre for Mental Health, Swinburne University of Technology, Melbourne, Australia; School of Population and Global Health, University of Melbourne, Melbourne, Australia

    3 shared publications
  • Jerome Sarris

    Psychae Institute, Melbourne, Australia; Centre for Mental Health, Swinburne University of Technology, Melbourne, Australia; The Florey Institute of Neuroscience and Mental Health & The Department of Psychiatry, Melbourne University, Melbourne, Australia; NICM Health Research Institute, Western Sydney University, Westmead, NSW, Australia

    3 shared publications
  • Nige Netzband

    Department of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom

    3 shared publications
  • Sam Gandy

    Onaya Science Iquitos Peru

    3 shared publications
  • Allan H. Young

    Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London & South London and Maudsley NHS Foundation Trust, Bethlem Royal Hospital, Beckenham, United Kingdom

    2 shared publications

Latest Publications

  • Open Access

    Acute experiences and persisting psychological effects associated with an encapsulated DMT-harmala alkaloid combination: results of a phase 1 study

    by Daniel Perkins, Andreas Halman, Anna Urokohara, Joeseph Palumbo, Mitchell Low, Simon Ruffell, Nicole Galvão-Coelho, Lisa Collins, Amanda Norman, Jerome Sarris

    Acute subjective experiences induced by psychedelics have been identified as important mediators of therapeutic outcomes in many studies. Mystical experiences specifically, have been correlated with a range of therapeutic outcomes including reductions in symptoms of depression, anxiety and addiction. This paper assesses acute subjective experiences induced by an encapsulated DMT-harmala alkaloid product and associations with persisting psychological effects. Botanically derived purified and partially purified formulations containing precise levels of DMT and three harmala alkaloids were administered in 17 dosing sessions to 9 healthy volunteers, with acute subjective experiences data collected via three psychometric instruments (MEQ-30, 5D-ASC, and newly adapted SIME). Pearson's correlations and linear mixed models investigated dose-response relationships and associations with persisting psychological effects. Further analysis compared acute subjective experience scores in this study to ayahuasca drinkers in various naturalistic contexts. Strong, significant positive correlations were identified between total dose and MEQ and SIME scores. The purified DMT-harmala formulation reliably elicited strong acute subjective experiences, with scores exceeding those reported in most previous studies. These experiences were robustly associated with a range of beneficial persisting psychological effects. Findings suggest that this formulation warrants further investigation in controlled clinical trials with relevant patient populations to assess therapeutic potential and safety.


  • Open Access

    Psychedelic medicine and cultural responsiveness: A call for Aboriginal and Torres Strait Islander engagement in Australian clinical trials and practice

    by Bianca Sebben, Jem Stone, Jerome Sarris, Daniel Perkins, Kirt Mallie, Scarlet Barnett, Simon G.D. Ruffell, Vanessa L. Beesley


  • Open Access

    Corrigendum: Ceremonial ayahuasca in amazonian retreats—mental health and epigenetic outcomes from a six-month naturalistic study

    by Simon G. D. Ruffell, Nige Netzband, WaiFung Tsang, Merlin Davies, Antonio Inserra, Matthew Butler, James J. H. Rucker, Luís Fernando Tófoli, Emma Louise Dempster, Allan H. Young, et al.

    Corrigendum: Ceremonial ayahuasca in amazonian retreats—mental health and epigenetic outcomes from a six-month naturalistic study


  • Open Access

    Insights, Life Changes and Lifestyle Changes Reported by Individuals Consuming Ayahuasca in Naturalistic Settings: Nature, Frequency and Associations with Mental Health and Wellbeing

    by Daniel Perkins, Emerita Opaleye, Jose Carlos Bouso, Luis Fernando Tófoli, Jerome Sarris, Violeta Schubert, Simon Ruffell, Hana Simonova

    Background: In the context of increasing scientific interest in the potential therapeutic use of psychedelic agents and their underlying psychotherapeutic mechanisms, we undertake the first detailed assessment of insights and life and lifestyle changes associated with ayahuasca consumption. Methods: An international cross-sectional study of ayahuasca drinkers in a variety of settings was performed (n = 8907). Bivariate analysis and multivariate linear and logistic regressions were used to explore associations between a range of covariates and insights, life changes and lifestyle changes. The least absolute shrinkage and selection operator variable selection method (LASSO) was used to select the variables most relevant for inclusion in models assessing broader wellbeing and mental health associations. Results: Insights are almost universally reported as part of the ayahuasca experience and are highly valued by drinkers and strongly predictive of subsequent beneficial life and lifestyle changes. A range of personal, vocational, religious/spiritual and health-related life changes (attributed to ayahuasca) are also commonly identified, as are various beneficial lifestyle and health behavior changes. Demographic and ayahuasca drinking variables that are predictive of such phenomena are reported, along with associations between insights, life and lifestyle changes and perceived growth in psychological wellbeing and current mental health status (Kessler 10 and SF-12 MCS). Conclusion: Insights and subsequent life and lifestyle changes appear to have a central role in the transformative effects reported by individuals consuming ayahuasca, with these occurring across contexts of use and demographic groups.


  • Open Access

    Ayahuasca: A review of historical, pharmacological, and therapeutic aspects

    by Simon G. D. Ruffell, Max Crosland‐Wood, Rob Palmer, Nige Netzband, WaiFung Tsang, Brandon Weiss, Sam Gandy, Tessa Cowley‐Court, Andreas Halman, Diana McHerron, et al.

    Ayahuasca is a psychedelic plant brew originating from the Amazon rainforest. It is formed from two basic components, the Banisteriopsis caapi vine and a plant containing the potent psychedelic dimethyltryptamine (DMT), usually Psychotria viridis. Here we review the history of ayahuasca and describe recent work on its pharmacology, phenomenological responses, and clinical applications. There has been a significant increase in interest in ayahuasca since the turn of the millennium. Anecdotal evidence varies significantly, ranging from evangelical accounts to horror stories involving physical and psychological harm. The effects of the brew on personality and mental health outcomes are discussed in this review. Furthermore, phenomenological analyses of the ayahuasca experience are explored. Ayahuasca is a promising psychedelic agent that warrants greater empirical attention regarding its basic neurochemical mechanisms of action and potential therapeutic application.


  • Open Access

    New study investigates the impact of Amazonian ayahuasca retreats on veterans, assessing its effect on brainwaves, the genome, gut microbiome and mental health

    by Simon Ruffell

    New study investigates the impact of Amazonian ayahuasca retreats on veterans, assessing its effect on brainwaves, the genome, gut microbiome and mental health

  • Open Access

    Ayahuasca – a review of historical, pharmacological, and therapeutic aspects

    by Simon Ruffell, Nigel Netzband, WaiFung Tsang, Sam Gandy, Daniel Perkins, Tessa Cowley-Court, Andreas Halman, Diana McHerron, Tom Kennedy, Eleanor White, et al.

    Ayahuasca is a psychedelic plant brew originating from the Amazon Rainforest. It is formed from two basic components, the Banisteriopsis caapi vine, and a plant containing the potent psychedelic dimethyltryptamine (DMT), usually Psychotria viridis. Here we review the history of this brew and describe recent work on its pharmacology and phenomenological responses to, and clinical applications of ayahuasca. There has been a significant increase in interest surrounding ayahuasca since the turn of the millennium. Increasing numbers of tourists are travelling to the Amazon rainforest to drink the brew, with various media outlets, celebrities, and researchers describing benefits from its consumption. Ayahuasca is now present across the globe and retreat centres offering plant medicine experiences has become a thriving business. Anecdotal evidence varies significantly, ranging from evangelical accounts to horror stories involving physical and psychological harm. The effects of the brew on personality, mental health outcomes, and nature-relatedness are discussed in this review. Further, phenomenological analyses of the ayahuasca experience are explored. Ayahuasca is a promising psychedelic agent that warrants greater empirical attention regarding its basic neurochemical mechanisms of action and its therapeutic uses.


  • Open Access

    Participation in an indigenous Amazonian led ayahuasca retreat associated with increases in nature relatedness – a pilot study

    by Simon Ruffell, Sam Gandy, WaiFung Tsang, Nigel Netzband, Jack Hollingdale

    Indigenous Amazonian shamanic ayahuasca practice is deeply rooted in nature and it is employed as an ecological mediating agent and in collective environmental decision-making processes by some of the groups that use it. Phenomenologically, the ayahuasca experience is often rich in nature-based themes and content, and its usage has been associated with eliciting shifts in perspectives and attitudes towards nature. In this proof of concept study, participation in an ayahuasca retreat in a traditional indigenous Amazonian context (with a mean of 5.85 ceremonies attended) was associated with significant increases in nature relatedness (n = 24; Cohen’s d = .51) and mindfulness (n = 38; Cohen’s d = .75), and improvements in depression (n = 47; Cohen’s d = 1.18), state anxiety (n = 47; Cohen’s d = 1.02), and trait anxiety (n = 42; Cohen’s d = .88). Furthermore, significant negative correlations were found between changes in nature relatedness and depression (r = .623, p = .001), state anxiety (r = -.542, p = .008), and trait anxiety (r = -.485, p = .022), with a significant positive correlation between change in nature relatedness and mindfulness (r = .747, p = .001). It is currently unclear if the changes seen were due to consumption of the brew, participation in ceremony, or the retreat setting itself. Although this pilot study suggests a potential therapeutic role for Amazonian ayahuasca retreats as a multidimensional intervention, further work is required to assess the role of possible mediators underlying such shifts, while evaluating to what extent these are sustained long-term.


  • Open Access

    Ceremonial Ayahuasca in Amazonian Retreats—Mental Health and Epigenetic Outcomes From a Six-Month Naturalistic Study

    by Simon G. D. Ruffell, Nige Netzband, WaiFung Tsang, Merlin Davies, Matthew Butler, James J. H. Rucker, Luís Fernando Tófoli, Emma Louise Dempster, Allan H. Young, Celia J. A. Morgan

    Ayahuasca is a natural psychoactive brew, used in traditional ceremonies in the Amazon basin. Recent research has indicated that ayahuasca is pharmacologically safe and its use may be positively associated with improvements in psychiatric symptoms. The mechanistic effects of ayahuasca are yet to be fully established. In this prospective naturalistic study, 63 self-selected participants took part in ayahuasca ceremonies at a retreat centre in the Peruvian Amazon. Participants undertook the Beck Depression Inventory (BDI-II), State-Trait Anxiety Inventory (STAI), Self-compassion Scale (SCS), Clinical Outcomes in Routine Evaluation-Outcome Measure (CORE-OM), as well as secondary measures, pre- and post-retreat and at 6-months. Participants also provided saliva samples for pre/post epigenetic analysis. Overall, a statistically significant decrease in BDI-II (13.9 vs. 6.1,p< 0.001), STAI (44.4 vs. 34.3p< 0.001) scores, and CORE-OM scores were observed (37.3 vs. 22.3p< 0.001) at post-retreat, as well as a concurrent increase in SCS (3.1 vs. 3.6,p< 0.001). Psychometric improvements were sustained, and on some measures values further decreased at 6-month follow-up, suggesting a potential for lasting therapeutic effects. Changes in memory valence were linked to the observed psychometric improvements. Epigenetic findings were equivocal, but indicated that further research in candidate genes, such as sigma non-opioid intracellular receptor 1 (SIGMAR1), is warranted. This data adds to the literature supporting ayahuasca's possible positive impact on mental health when conducted in a ceremonial context. Further investigation into clinical samples, as well as greater analyses into the mechanistic action of ayahuasca is advised.


  • Open Access

    Modulatory effects of ayahuasca on personality structure in a traditional framework

    by Nige Netzband, Simon Ruffell, S. Linton, W. F. Tsang, T. Wolff

    Ayahuasca is a psychoactive plant brew containing dimethyltryptamine (DMT) and monoamine oxidase inhibitors (MAOIs). It originates from the Amazon basin, where it is used primarily for ceremonial purposes. Ayahuasca tourists are now entering certain communities seeking alternative physical or psychological healing, as well as spiritual growth.Rationale: Recent evidence has shown that the similar acting psychedelic compound, psilocybin, facilitated long-term increases in trait openness following a single administration.Objectives: This paper assesses the impact of ayahuasca on personality in a traditional framework catering for ayahuasca tourists.Method: Within a mixed design, we examined the effect of ayahuasca on participants’ personality (measured by the NEO Personality Inventory 3 questionnaire) across time (pre- to post-ayahuasca administration, and 6-month follow-up), relative to a comparison group (who did not ingest ayahuasca).Results: The results demonstrated significant increases in agreeableness pre- and post-ayahuasca administration and significant reductions in neuroticism in 24 participants, relative to the comparison group. Both of these changes were sustained at 6-month follow-up, and trait level increases were also observed in openness at this stage. Additionally, greater perceived mystical experience (measured using the Mystical Experience Questionnaire 30) was associated with increased reductions in neuroticism.Conclusions: These findings, which indicate a positive mediating effect of ayahuasca on personality, support the growing literature suggesting potential therapeutic avenues for serotonergic psychedelics.